NEMUS Bioscience Inc. is a biopharmaceutical company focused on discovering, developing and commercializing new chemical entities from a class of chemically diverse compounds called cannabinoids. The company's product candidates in preclinical stage include NB1111 for the treatment of glaucoma; and NB1222 used for treating chemotherapy induced nausea and vomiting. Its products under research comprise NB3111 for the treatment of methicillin-resistant Staphylococcus aureus, as well as NB2111 for use in treating chemotherapy induced peripheral neuropathy. The company was founded in 2012 and is headquartered in Costa Mesa, California.
NEMUS Bioscience Inc., a Nevada corporation, is a SEC fully reporting company listed on the under the symbol NMUS.
Company website: http://www.nemusbioscience.com/home.html
Filings and disclosure with Level 2 quotes: http://www.otcmarkets.com/stock/NMUS/quote
600 ANTON BLVD, SUITE 1100, COSTA MESA, CA 92626
NMUS Security Details
Share Structure - as of Nov 28, 2016
Authorized Shares: 236,000,000
Outstanding Shares: 20,798,163
- Restricted 13,594,621
- Unrestricted 7,546,042
Transfer Agent: Clear Trust, LLC